Header Logo

Connection

YOCHAI BIRNBAUM to Cyclooxygenase 2

Back to Details
This is a "connection" page, showing publications YOCHAI BIRNBAUM has written about Cyclooxygenase 2.
YOCHAI BIRNBAUM
Connection Strength
2.469
Cyclooxygenase 2
  1. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014 Sep; 34(9):2078-85.
    View in: PubMed
    Score: 0.410
  2. Pleiotropic effects of statins: the role of eicosanoid production. Curr Atheroscler Rep. 2012 Apr; 14(2):135-9.
    View in: PubMed
    Score: 0.351
  3. Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-?-independent manner. Basic Res Cardiol. 2011 May; 106(3):431-46.
    View in: PubMed
    Score: 0.325
  4. The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol. 2008 Jul; 295(1):H343-51.
    View in: PubMed
    Score: 0.268
  5. The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. J Cardiovasc Pharmacol Ther. 2007 Jun; 12(2):98-111.
    View in: PubMed
    Score: 0.251
  6. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol. 2006 May; 290(5):H1960-8.
    View in: PubMed
    Score: 0.226
  7. Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine. Cardiovasc Drugs Ther. 2016 Dec; 30(6):539-550.
    View in: PubMed
    Score: 0.121
  8. Resolvin E1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H153-64.
    View in: PubMed
    Score: 0.077
  9. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010 Apr; 24(2):107-20.
    View in: PubMed
    Score: 0.076
  10. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol. 2008 Dec; 295(6):H2436-46.
    View in: PubMed
    Score: 0.069
  11. Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2. Prostaglandins Other Lipid Mediat. 2007 Aug; 84(1-2):43-53.
    View in: PubMed
    Score: 0.062
  12. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol. 2007 Jun; 292(6):H2891-7.
    View in: PubMed
    Score: 0.061
  13. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins Other Lipid Mediat. 2007 Feb; 83(1-2):89-98.
    View in: PubMed
    Score: 0.060
  14. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol. 2006 Sep; 291(3):H1158-69.
    View in: PubMed
    Score: 0.058
  15. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res. 2005 Feb 01; 65(2):345-55.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.